Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.

Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...

On the heels of a move to reduce its viral vector manufacturing workforce, Thermo Fisher is beefing up its biologics ...

Blood test maker Grail has recruited ‘Grey’s Anatomy’ star Kate Walsh to join a campaign focused on encouraging Gen Xers to ...

HHS secretary Robert F. Kennedy Jr. has been on the receiving end of two heated letters from lawmakers outlining the threats ...

Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...

In a bid to break into the CDMO business at one of its most lucrative angles, India's Granules is snapping up Swiss contract ...

Author:  Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes, UCB | Hear from UCB’s Brad Chapman on the importance of ...

The approval makes chenodiol—already cleared for decades to treat radiolucent gallstones under the brand name Chenodal—the ...

A new awareness campaign from Abbott highlights a major sticking point in diabetes management: the harmful impact of societal ...

With a $430 million buyout of Australia’s Mayne Pharma locked down, Cosette Pharmaceuticals is looking to become a leading ...